Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic, Lung LB

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement and compliance with the US FDA Lab Developed Test ruling.